

### Equity Review

The MSCI India Index started the month at 18.22 and closed at 17.69, decreasing by 3% over the month. As per latest data, FIIs were net sellers in Equity with outflow of USD ~2.18 Bn and net buyers in Fixed Income with inflow of USD ~1.60 Bn. Domestic Institutions were net buyers in equities with net inflow of USD ~2.56 Bn in the month.

### Commodities and Inflation

NYMEX Crude Oil prices corrected by 5.95% from the previous month levels, ending at 55.10 per barrel; the prices were lower by ~21.1% yoy. LME closed at 2757.3 lower by 2.0% over the previous month (lower by ~5.8% yoy). Gold prices closed at USD 1525.73/oz ~6.6% higher from the previous month level (higher by ~26.4% yoy). The USD Index strengthened by ~0.4% vs. other currencies over the month; over the year the USD Index was higher by ~3.9%. July's CPI inflation came in at 3.15% y-o-y compared to 3.2% last month. Core inflation (ex food, fuel, petrol, diesel, and housing) came in at 4.24% compared to 4.13% in June; while food inflation moderated marginally to 2.33% from 2.4% previously. Fuel and light inflation contracted 0.36%, housing inflation was marginally up at 4.87% from 4.84% a month ago and clothing and footwear inflation was seen at 1.65% against 1.52% in June. The cumulative CPI inflation has declined to 3.09% in April-July FY2020 compared with 4.63% in April-July FY2019

### Markets & Real Economy

The Index of Industrial Production increased by 2.0% in June compared to 3.1% in the previous month. Mining, Manufacturing & Electricity grew 1.6%, 1.2% and 8.2% respectively. Output of primary goods grew by 0.5% while intermediate goods inched up by 12.4%. Similarly, output of consumer non-durables rose 7.78, however, consumer durables slipped -5.5%. Output of infrastructure or construction goods fell by 1.8%, and that of capital goods declined by 6.5%. The cumulative growth for the period April-June 2019 over the corresponding period of the previous year stands at 3.6%.

As per the latest RBI data, Foreign

exchange reserves position improved to USD 429.05 Bn over the month. The Rupee depreciated by ~3.84% over the month closing at 71.465 Rs/USD vs. 68.823 Rs/USD last month.

### Monetary Policy

Prioritizing growth revival by boosting aggregate demand, RBI deemed appropriate to reduce the policy rate by 35 bps to 5.4% in the August Monetary Policy. Dovish developments globally, announcement of rate easing by leading Central banks including the Fed and RBI's change in stance to 'accommodative' in the previous policy facilitated the 35 bps rate cut. CPI projections were largely unchanged from the June policy and Q1FY21 CPI was projected at 3.6%. RBI revised FY20 GDP lower to 6.9% (from 7% earlier) citing slowdown in growth momentum in advanced economies due to US-China trade tensions and geopolitical uncertainty and weak economic activity in Emerging Markets. RBI is expected to continue to ensure transmission of 110bps rate easing done so far via adequate liquidity. Scope for further easing remains, given that aggregate demand needs a meaningful boost and inflation is likely to stay within target levels.

### Sector-wise Performance

Key outperforming sector during the month was Information Technology. Following the strong momentum over the previous month, IT stocks continued to remain positive in an otherwise subdued market as growth outlook remained steady. Weakening of the INR further supported sentiment for IT stocks as depreciation in the currency impacts the sector positively by way of higher realizations and improvement in margins. Given that the top tier companies in the sector continue to grow by 10-12% in an environment where the economy is struggling to growth at 10-12% nominal GDP growth rate, provides support to the steady growth profile of Indian IT companies. We continue to remain positive on the sector.

Key underperforming sector during the month was Metals. The sector has been one of the most impacted sectors during the weakness in markets as the US-China trade war continues to

escalate. With no end to the trade issues in sight, outlook for global growth has deteriorated leading to lower demand for commodities and weakness in pricing. We have always maintained that the sector lacks long term growth visibility and pricing power and the highly cyclical nature of the business leads to sharp upswings and downswings. We maintain our negative stance on the sector.

### Key Stock Movements

**Ajanta Pharma** – Ajanta Pharma is a pharmaceutical company with diversified presence across India, Asia, Africa and US markets. The company has seen some deterioration in earnings growth over the past year due to muted growth in Asia and Africa geographies and pressure on margins due to commercializing of new facilities. However, in the Q1FY20 results, the company has delivered a marked improvement in revenue growth driven by new product launches in US market and stabilization of Asia and Africa markets. In addition, margins have also started to improve as the fixed costs for the new plants get absorbed. With improving growth outlook and gradual improvement in margins, the company shall deliver healthy earnings growth going ahead. The company has a long track record of generating very healthy Return on Capital and Free Cash Flows.

**RBL Bank** – The bank has faced some stress on its corporate exposure which has led to the management guiding for higher credit costs during the current year. This has also led to improvement of Return on Assets from 1.25% to 1.5% getting deferred by a year which has led to a de-rating of the stock. The management has however guided that the stress shall be limited to the current financial year only and shall get normalized during FY21. The bank is adequately capitalized with sufficient Tier 1 capital for the next few quarters. We are not adding exposure aggressively and are monitoring the corporate book closely. We may add to our exposure depending on the visibility of reduction in corporate stressed book and improvement in RoA.

# EQUITY & FIXED INCOME OUTLOOK

August 2019

## Market Outlook

Sentiment in the equity market has deteriorated as the global outlook continues to worsen driven by US-China trade concerns, slowing growth in all major economies and rising risk aversion. On the domestic front, constrained credit, indifferent exports and Government's hard stand of fiscal restraint have led to weakened growth. While Monetary policy has turned accommodative, transmission of the same has been restricted. Further rate cuts by RBI, concentrated efforts to ensure their transmission, and some form of fiscal stimulus by the Government are needed to revive the growth momentum and bring it back towards the long term potential growth rate. The Government, taking cognizance of the situation, has announced a few measures over the last couple of weeks and more steps are likely going forward. The Indian economy has immense long term growth potential and timely moves by the Government can ensure that the economy reclaims its high growth trajectory. In the meantime, any further weakness in the equity market will lead to valuations getting attractive and will provide opportunity for long term investors to increase their exposure to Indian equities.

## Fixed Income Review

India's consumer prices (CPI) held broadly steady at 3.15% in July 2019 from 3.18% in June 2019 even though there was an upward sequential momentum in both food and core inflation. Food inflation continued its upward momentum, increasing by 2.36% in July 2019 as compared to an increase of 2.25% in June 2019, primarily on account of sharp rise in prices of vegetables and fruits. The core-CPI inflation also inched up to 4.3% in July 2019 as compared to 4.1% in June 2019, driven by higher sequential momentum in housing component, clothing & footwear as well as the miscellaneous basket. Fuel inflation moderated sharply to 0.4% in July 2019 from a level 2.3% in June 2019 led by sharp contraction in LPG prices and contraction in coal and charcoal prices. The Wholesale Price Index (WPI) decelerated to 1.1% in July 2019 from 2.0% in June 2019 on account of broad-based moderation across food, fuel and core inflation.

In its third bi-monthly policy review for FY2020, RBI Monetary Policy Committee (MPC) opted for incremental monetary easing. However, in a departure from usual convention of changing benchmark rates by 25 bps (or multiples thereof), the repo rate was reduced by 35 bps to 5.40%. While all MPC members voted for incremental monetary easing, four out of six voted in favour of a 35 bps cut, with the other two voting for a 25 bps cut. The MPC unanimously retained the monetary policy stance at 'accommodative'. The RBI continues to forecast inflation trajectory at sub 4% levels over the next four quarters. Inflation forecasts for FY2020 were revised marginally higher to 3.35% with H1FY2020 forecasts of 3.1% and H2FY2020 3.5-3.7%, with risks evenly balanced. More importantly Q1FY2020 inflation projections are at 3.6%, below the 4% inflation target.

India's GDP growth slowed to 5.0% during Q1FY2020 as compared with 8.0% during same period last year. Slowdown in domestic private demand amidst lacklustre private investment coupled with a global slowdown led to record low nominal GDP. Gross Value Added (GVA) growth for Q1FY2020 fell sharply to 4.9% YoY vs 7.7% earlier led by a higher than expected moderation in the manufacturing sector.

## Outlook

RBI's MPC move to cut the interest rates by 35 bps was a pre-emptive one given slowing growth prospects domestically and globally. This move by the RBI was in cognizance with the global central banks which have adopted dovish stance in support of growth. Going forward, with the inflation trajectory remaining in the RBI comfort zone, any surprise on the downside on the growth front led by both domestic and global factors, could prompt the RBI's MPC towards further accommodation in future monetary policy reviews. The lower than expected first quarter GDP number indicates that the slowdown is more pervasive, underscoring the need for coordinated monetary support and fiscal policy actions. Therefore, we expect further monetary support with the terminal repo rate moving towards 5% in next 3 to 6 months.

The entire fixed income component is invested into sovereign bonds with majority exposure positioned towards the front end of the yield curve in order to generate carry by taking minimal credit as well as lower duration risk.

## Important Legal Information

### Guernsey

UTI International Ltd, Guernsey (UTI IL) is a regulated entity in Guernsey, governed by Guernsey law, and is under the Protection of Investors (Bailiwick of Guernsey) Law 1987.

### Hong Kong

The distribution of this document/ the prospectus / KIID or any marketing material ("this material") of the Fund ("the Fund"), may only be made in Hong Kong in circumstances that do not constitute an issue, invitation or offer to the public under the Hong Kong Securities and Futures Ordinance ("Securities and Futures Ordinance"). This material is confidential to you. The contents of this material have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offering of the shares described in this material. If you are in any doubt about any of the contents of this material, you should obtain independent professional advice. The Fund has not been authorized by the Securities and Futures Commission in Hong Kong pursuant to Section 104 of the Securities and Futures Ordinance nor has the offering memorandum been registered by the Registrar of Companies in Hong Kong pursuant to the Hong Kong Companies Ordinance ("Companies Ordinance"). Accordingly, unless permitted by the Securities and Futures Ordinance no person may issue or have in its possession for issue in Hong Kong this material or any other invitation, advertisement or document relating to the Participating Shares interests in the Fund to anyone other than (1) to professional investors within the meaning of the Securities and Futures Ordinance and any rules made there under, (2) to persons and in circumstances which do not constitute an invitation or offer to the public within the meaning of the Securities and Futures Ordinance or the Companies Ordinance, or (3) otherwise pursuant to, and in accordance with the conditions of, any other applicable provisions of the Securities and Futures Ordinance and the Companies Ordinance.

### Ireland

The Fund is an open-ended investment company with variable capital incorporated with limited liability in Ireland under the Companies Acts, 1963 to 2012 with registration number 516063 and established as an undertaking for collective investment in transferable securities pursuant to the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011). The Fund is both authorised and supervised by the Central Bank. Authorisation of the Fund by the Central Bank shall not constitute a warranty as to the performance of the Fund and the Central Bank shall not be liable for the performance or default of the Fund. The authorisation of the Fund is not an endorsement or guarantee of the Fund by the Central Bank and the Central Bank is not responsible for the contents of the Prospectus of the Fund.

### Singapore

The Fund is a recognised scheme under the Securities and Futures Act, Chapter 289 of Singapore ("SFA"). A copy of the Singapore Prospectus has been lodged with and registered by the Monetary Authority of Singapore ("MAS"). Investors from Singapore must read the Singapore prospectus and the product highlights sheet before making any investment decision. The MAS assumes no responsibility for the contents of the Singapore Prospectus. Registration of the Singapore Prospectus by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with. The MAS has not, in any way, considered the investment merits of the Company. The distribution of this Singapore Prospectus and the offering or sale of the Shares in the Company in some jurisdictions may be restricted or prohibited. Persons who have possession of the Singapore Prospectus of the Fund must inform themselves about and observe such restrictions or prohibitions.

### Switzerland

The Company is authorized for public distribution in and from Switzerland by the Swiss Financial Market Supervisory Authority ("FINMA"). Investors from Switzerland should read the Consolidated Prospectus for use solely in Switzerland. The representative and paying agent in Switzerland is RBC Investor Services Bank S.A., Esch-sur-Alzette, Zurich Branch, Bleicherweg 7, CH-8027 Zurich, Switzerland (the "Representative"). In Switzerland, the funds prospectus, Key Investor Information Document (KIID), the articles of association, the annual and semi-annual reports may be obtained free of charge from the Representative. In respect of the units distributed in and from Switzerland, the places of performance and jurisdiction is the registered office of the Representative.

### United Arab Emirates

The Fund is registered with the Securities and Commodities Authority ("SCA") of UAE as a foreign investment fund. The fund

can be offered and marketed by licensed distributor who has individually obtained approval from SCA to distribute this Fund. The information on the list of licensed distributor for this fund will be available from the investment manager of the Fund.

### U.K

Any financial promotion contained herein, as defined by UK regulations, has been approved by UTI International Limited (FCA no:183361); a firm authorised and regulated by the Financial Conduct Authority ("FCA") U.K. The Fund mentioned herein has been recognised by the FCA pursuant to section 264 of the FSMA. Facilities Agent is UTI International Limited, 120 New Cavendish Street, London W1W 6XX, United Kingdom.

Copies of the legal documents can be obtained in English, free of charge, from the Facilities Agent at 120 New Cavendish Street, London W1W 6XX, United Kingdom. The promotion of the Company in the United Kingdom can be carried out by persons authorized to carry on investment business in the United Kingdom under the FSMA and is not subject to the restrictions on promotion contained in section 238 of the FSMA. The FCA has not approved and takes no responsibility for the contents of the Prospectus or the UK Country Supplement or for any document referred to in them, nor for the financial soundness of the Fund or for the correctness of any statements made or expressed in the Prospectus or the UK Country Supplement or any document referred to in them.

### United States of America

The Shares have not been nor will they be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or registered or qualified under the securities laws of any of the states of the United States. The Shares may not be offered, sold or delivered directly or indirectly in the United States or to or for the account or benefit of any "U.S. Person" (as defined in Regulation S under the 1933 Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the 1933 Act and any applicable state securities laws. Neither the Company nor any Fund will be registered under the U.S. Investment Company Act of 1940, as amended (the "1940 Act"), pursuant to Section 3(c)(7) of the 1940 Act. Accordingly, Shares will only be sold to "U.S. Persons", as defined in Regulation S under the 1933 Act, who are "qualified purchasers", as defined in the 1940 Act or the regulations thereunder, or as otherwise consistent with Section 3(c)(7) of the 1940 Act. Each subscriber for Shares that is a U.S. Person, as defined in Regulation S under the 1933 Act will be required to certify that it is both an "accredited investor" as defined in Regulation D under the 1933 Act and a "qualified purchaser" as defined in Section 2(a)(51) of the 1940 Act or the regulations thereunder. The qualifications for an "accredited investor" and a "qualified purchaser" are set out in detail in Appendix III to this Prospectus. The Shares have not been approved or disapproved by the U.S. Securities and Exchange Commission (the "SEC") or any state securities commission, nor has any such regulatory authority passed upon or endorsed the merits of this offering or the accuracy or adequacy of this Prospectus. Any representation to the contrary is unlawful. The Directors do not intend to permit Shares of any Fund of the Company acquired by investors subject to the United States Employee Retirement Income Security Act of 1974, as amended ("ERISA"), and by other benefit plan investors, as defined in ERISA, to equal or exceed 25% of the value of any such Class (determined in accordance with ERISA). Accordingly, each prospective applicant for Shares will be required to represent and warrant as to whether and to what extent he is a "benefit plan investor" for the purposes of ERISA. For additional information on investments by U.S. Persons, including certain U.S. securities law, U.S. federal tax, and ERISA and other benefit plan considerations, please see Appendix III to this Prospectus.

### Other jurisdictions

The distribution of this document of the Fund or Prospectus of the Fund and the offering of Shares of the Fund may be restricted in certain jurisdictions. This document or the Prospectus of the Fund does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not authorised or the person receiving the offer or solicitation may not lawfully do so. It is the responsibility of any person in possession of this document or the Prospectus of the Fund and of any person wishing to apply for Shares of the Fund to inform himself of and to observe all applicable laws and regulations of the countries of his nationality, residence, ordinary residence or domicile.

**This advertisement has not been reviewed by the Monetary Authority of Singapore.**